Implantation of the permanent jarvik-2000 left ventricular assist device
A single-center experience
Michael P. Siegenthaler, MD*,*,
J.ürgen Martin, MD*,
Andreas van de Loo, MD ,
Torsten Doenst, MD*,
Wolfgang Bothe, MD* and
Friedhelm Beyersdorf, MD*
* Department of Cardiovascular Surgery, University of Freiburg, Freiburg, Germany
Department of Cardiology, University of Freiburg, Freiburg, Germany
View larger version (66K):
[in a new window]
|
Figure 1 (A) The Jarvik-2000 left ventricular assist device is shown before implantation. Note that the device is only slightly larger than the surgeon’s thumb. (B) The power cable connected to the percutaneous skull-mounted pedestal is shown. There were no problems at the skin exit site. The black power plug connected to the percutaneous pedestal is waterproof, and the patient is able to take a shower. The inset shows an intraoperative view of the percutaneous skull-mounted pedestal.
|
|
View larger version (14K):
[in a new window]
|
Figure 2 The cardiac index of three patients as a function of the rotational speed of the Jarvik-2000 left ventricular assist device, measured with a Swan-Ganz catheter, one day after implantation.
|
|
View larger version (37K):
[in a new window]
|
Figure 3 Mild hemolysis after Jarvik-2000 implantation. The hemoglobin levels (A) became stabilized after the postoperative period. The persistent elevation of lactate dehydrogenase (LDH) levels (B) and reticulocytes (C) associated with decreased haptoglobin-levels (D) indicate some degree of trauma to the red blood cells. Note that Patient 3 was transfused on day 17; all other transfusions were given in the early postoperative period.
|
|
|
